# OnCo record ubamatamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ubamatamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ubamatamab" ;
  schema:name "Ubamatamab"@en ;
  schema:alternateName "REGN4018"@en ;
  schema:description "Ubamatamab (REGN4018) is Regeneron's investigational MUC16×CD3 bispecific antibody, in phase 1/2 and phase 2 trials for ovarian and endometrial cancer."@en ;
  schema:url <https://onco.cc/drugs/ubamatamab/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=Ubamatamab>, <https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS5632>, <https://doi.org/10.1111/cts.70082>, <https://clinicaltrials.gov/study/NCT03564340>, <https://clinicaltrials.gov/study/NCT06787612> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Bispecific T-cell engager (MUC16×CD3)" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/endometrial/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/muc16/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/regeneron/> ;
  onco:trials <https://onco.cc/trials/nct04590326/>, <https://onco.cc/trials/nct03564340/>, <https://onco.cc/trials/nct06787612/>, <https://onco.cc/trials/nct07154290/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-zhu-clin-transl-sci/> .